Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guidelines
  3. Paediatrics
  4. Back
  5. Gastroenterology (Paediatric)
  6. Proton Pump Inhibitor guideline for neonates and paediatrics (921)
Please update your RDS mobile app to version 4.7.1

We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.

You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits. 

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number.  To install latest updates:

On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Please get in touch with ann.wales3@nhs.scot with any questions.

Proton Pump Inhibitor guideline for neonates and paediatrics (921)

Use of Proton Pump Inhibitors (PPIs) in Neonates and Paediatrics.

1. Objectives
The aim of this guideline is to standardise prescribing practice of PPIs whilst ensuring patients are given appropriate and effective treatments.

2. Scope
This guideline covers the use of PPIs in neonates and paediatrics, across primary and secondary care, within NHS Greater Glasgow and Clyde. It is intended for use by all health professionals involved in the care of these patients.

3. Introduction
PPIs are indicated for use in patients for:

  • gastro-oesophageal reflux disease that has not responded to other treatments such as feed thickeners, alginates or H2-receptor antagonists (if supply resumes)
  • persistent or significant symptoms of reflux oesophagitis despite other measures
  • prevention or treatment of peptic ulceration (e.g. alongside long term steroids/NSAIDs)
  • H pylori eradication regimens

The need for ongoing treatment should be reviewed regularly and is particularly important for infant GORD.

Licensed suspensions of oral omeprazole are available, however there are limitations to the use of these products (see further advice section in attached document), and these products are not currently recommended for use for paediatric patients in NHSGGC.

Within general paediatrics, orodispersible tablet and capsule formulations of PPIs have been used successfully with little need for alternatives (see tables in attached document for further advice).

Resources

Use the button below to access this item.

Access this resource

Editorial Information

Last reviewed: 09/01/2024

Next review date: 31/01/2027

Author(s): Natalie Donald.

Version: 2

Approved By: Medicines Utilisation Subcommittee of ADTC